The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
- 126
- Biomarker+Development
Filter Results (2438)
- Target Advancement Program, 2018Investigating Alpha-synuclein Clumping in the Organoid Model of Parkinson's Disease
Study Rationale:
Alpha-synuclein -- a sticky protein that clumps in the brains of people with Parkinson's disease (PD) -- is a major target for the development of therapies for PD. Alpha-synuclein... - Inflammation Biomarkers Program, 2018The Role of Inflammation and Risk of Parkinson's Disease in People with GBA1 Mutations
Study Rationale:
Mutations (changes) in GBA1, the gene that directs the production of the glucocerebrosidase (GBA) protein, can increase the risk of Parkinson's disease (PD) in some people, but not in... - Mitochondrial Biomarkers Program, 2018Searching for Signs of Mitochondrial Breakdown in People with Parkinson’s Disease with an Unknown Cause
Study Rationale:
Some inherited forms of Parkinson's disease (PD) are caused by mutations (genetic changes) that lead to the breakdown of mitochondria, cell's energy generators. In some cases of... - Improved Biomarkers and Clinical Outcome Measures, 2018Does the Brain's Ability to Compensate for the Shortage of Dopamine Affect Parkinson's Disease Progression?
Study Rationale:
Parkinson's disease (PD) is a progressive disorder, but it is unclear what causes the gradual worsening of the symptoms over the years. It is also unknown why in some cases the disease... - Target Advancement Program, 2018Searching for Genes that Control Alpha-synuclein Levels in Parkinson's Disease
Study Rationale:
Alpha-synuclein is a sticky protein that clumps in the brains of people with Parkinson's disease (PD). The level of this protein in the brain correlates with the risk of Parkinson's... - Mitochondrial Biomarkers Program, 2018Developing Precision Biomarkers of Parkinson's Disease
Study Rationale:
Leucine-rich repeat kinase 2 (LRRK2) is the greatest known genetic contributor to Parkinson's disease (PD). Research studies have linked mutations (changes) in the LRRK2 gene to DNA...

Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.